STOCK TITAN

IMV - IMV STOCK NEWS

Welcome to our dedicated page for IMV news (Ticker: IMV), a resource for investors and traders seeking the latest updates and insights on IMV stock.

IMV Inc. is a dynamic biopharmaceutical company focused on the discovery and development of innovative immunotherapies. Specializing in cancer and infectious diseases, IMV's core business revolves around leveraging its unique delivery platform, DPX, to create potent and targeted treatments. The company’s flagship product, DPX-Survivac, is currently in clinical trials for multiple cancer indications. Recently, IMV has achieved significant milestones, including the initiation of Phase 2 clinical trials for their novel COVID-19 vaccine candidate, DPX-COVID-19.

IMV's strength lies in its robust pipeline and strategic partnerships with leading research institutions and pharmaceutical companies. Financially, IMV is backed by strong investor confidence, reflected in its stable stock performance and strategic funding rounds aimed at accelerating research and development efforts.

IMV's products aim to meet unmet medical needs by enhancing the body's immune response. The company continues to make strides in oncology, with promising results from recent studies indicating the potential of DPX-Survivac as a breakthrough treatment for ovarian cancer. In addition to oncology, IMV is expanding its focus to include infectious diseases, leveraging its DPX platform to address urgent global health challenges.

For more detailed updates on IMV's recent achievements, ongoing projects, and future plans, stay tuned to StockTitan for the latest news and insights.

Rhea-AI Summary

IMV Inc. has successfully closed a registered direct offering, selling 3,448,276 common shares and warrants at $2.61 per share, generating approximately $9 million in gross proceeds. The funds will support the clinical development of maveropepimut-S targeting diffuse large B cell lymphoma and ovarian cancer, as well as ongoing trials and the development of the DPX platform. The offering complies with Nasdaq rules and was facilitated by H.C. Wainwright & Co. No Canadian sales were made, and the securities were offered in the U.S. only, adhering to SEC regulations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

IMV Inc. has announced a registered direct offering for the sale of 3,448,276 common shares and warrants at a price of US$2.61 per share. The offering aims to raise approximately US$9 million, which will be allocated for the clinical development of its lead candidate, maveropepimut-S, in treating DLBCL and ovarian cancer, as well as for ongoing trials and general corporate purposes. The offering is expected to close on or about December 20, 2022. H.C. Wainwright & Co. is the exclusive placement agent for this transaction.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

IMV Inc. announced encouraging initial results from its VITALIZE Phase 2B trial of MVP-S, a treatment for relapsed, refractory Diffuse Large B Cell Lymphoma (r/r DLBCL). Patients who received at least three prior treatments showed complete responses, highlighting the potential of MVP-S in challenging cases. The trial involves up to 102 subjects and aims to evaluate the drug's efficacy when combined with pembrolizumab. Detailed results will be presented at the Immuno-Oncology 360° conference in February 2023, indicating a positive milestone for the company's immunotherapy portfolio.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary

IMV Inc. has announced the commencement of trading of its common shares post-consolidation, effective December 7, 2022, under the ticker IMV on Nasdaq. This share consolidation, approved by shareholders, occurs on a 1-for-10 basis, aimed at meeting Nasdaq's minimum bid price requirement of US$1.00 per share. IMV is a clinical-stage biopharmaceutical company focused on immune-educating therapies for solid and hematologic cancers, leveraging its DPX platform for cancer treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

IMV Inc. announced that shareholders approved a 1-for-10 reverse stock split at a special meeting on December 7, 2022. This consolidation will take effect at 5:00 PM ET on the same day, with trading on a split-adjusted basis beginning on December 13, 2022. The split aims to maintain compliance with Nasdaq's minimum bid price requirements. Following the split, approximately 8.24 million shares will be outstanding. The reverse stock split was approved by 87.87% of votes cast.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

IMV Inc. received a notification from Nasdaq regarding a deficiency in its Market Value of Listed Securities, which fell below the required $35 million for continued listing. The company has until May 22, 2023, to regain compliance. Despite this, trading of IMV shares will not be affected immediately, and it will continue to monitor its compliance status. Additionally, IMV will hold a special meeting on December 7, 2022, to consider a proposed share consolidation, which has received positive recommendations from independent proxy advisors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

IMV announced its financial and operational results for Q3 2022, highlighting progress in clinical trials for the immune-educating therapy MVP-S, aimed at treating various cancers. The VITALIZE Phase 2B trial for r/r DLBCL and AVALON Phase 2B trial for ovarian cancer are key focuses, with results expected in early 2023. The company restructured operations, reducing its workforce by one-third to concentrate resources on MVP-S. Financially, IMV reported a net loss of $8.9 million for Q3 2022, with cash reserves at $21.7 million, compared to $38.6 million at the end of 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

IMV Inc. (Nasdaq: IMV; TSX: IMV) announced a conference call and webcast scheduled for November 11, 2022, at 8:00 a.m. ET to discuss its 2022 third quarter financial and operational results. Analysts can register via a provided link, while others can access the audio webcast on IMV's website. The company focuses on developing therapies using its DPX platform to treat cancers, with lead candidate maveropepimut-S (MVP-S) showing promise in clinical trials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

IMV Inc. (Nasdaq: IMV) announced recent progress in its VITALIZE study, evaluating maveropepimut-S (MVP-S) for relapsed or refractory diffuse large B cell lymphoma (r/r DLBCL). Enrollment has accelerated, indicating strong interest in MVP-S, which combines with pembrolizumab and low-dose cyclophosphamide. The company aims to validate MVP-S and its DPX platform through Phase 2b trial outcomes, with findings expected to be presented at a scientific conference in early 2023. Positive clinical results indicate MVP-S's potential in enhancing patient responses in this challenging cancer type.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

IMV Inc. has announced a strategic reorganization aimed at enhancing shareholder value. This includes a significant workforce reduction of about one third to concentrate resources on key clinical programs, particularly the Phase 2B VITALIZE trial for relapsed/refractory DLBCL and the AVALON trial for advanced ovarian cancer. Dr. Saman Maleki has been appointed to the Board of Directors, and Brittany Davison has been promoted to Chief Accounting Officer. An early clinical update on the VITALIZE trial is set for September.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none

FAQ

What is the market cap of IMV (IMV)?

The market cap of IMV (IMV) is approximately 9.8M.

What is IMV Inc.'s main focus?

IMV Inc. focuses on developing innovative immunotherapies for cancer and infectious diseases using their proprietary DPX platform.

What is DPX-Survivac?

DPX-Survivac is IMV's flagship product, a novel immunotherapy currently in clinical trials for various cancer indications.

What recent achievements has IMV Inc. made?

IMV has recently initiated Phase 2 clinical trials for their COVID-19 vaccine candidate, DPX-COVID-19, and reported promising results for DPX-Survivac in treating ovarian cancer.

What is the DPX platform?

The DPX platform is IMV's unique delivery system designed to enhance the potency and targeting of immunotherapies.

How is IMV Inc. financially performing?

IMV shows stable financial performance, supported by strategic funding rounds and strong investor confidence.

Who are IMV Inc.'s partners?

IMV has strategic partnerships with leading research institutions and pharmaceutical companies to advance their clinical programs.

What types of diseases is IMV targeting?

IMV is targeting cancer and infectious diseases, leveraging their DPX platform to develop effective immunotherapies.

Where can I find the latest news on IMV Inc.?

You can find the latest news and updates on IMV Inc. on the StockTitan website.

What are IMV's future plans?

IMV plans to expand its clinical trials, develop new partnerships, and further explore the potential of its DPX platform for new indications.

How does IMV's DPX platform work?

The DPX platform works by enhancing the delivery and potency of immunotherapies, making treatments more effective and targeted.

IMV

Nasdaq:IMV

IMV Rankings

IMV Stock Data

9.81M
10.17M
0.41%
20.37%
2.66%
Biotechnology
Healthcare
Link
Canada
Dartmouth